Download PDF
Aktuelle Urol 2000; 31(6): 341-346
DOI: 10.1055/s-2000-8989
ÜBERSICHT
Georg Thieme Verlag Stuttgart ·New York

Urologische Bedeutung

CUP - Cancer of unknown primary siteM. König, S. Shadouh1 , F. Boeminghaus
  • Urologische Klinik, Städtische Kliniken Neuss
  • 1Pathologisches Institut, Städtische Kliniken Neuss
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Metastasen eines unbekannten Primärtumors CUP treten in 0,4 bis 7 Prozent aller Tumoren auf. Umfangreiche und kostspielige Diagnostik führt nur selten zur Diagnose des Primarius und hat keinen Einfluss auf die mittlere Überlebenszeit. Für die meisten Patienten kommt lediglich eine palliative Behandlung in Betracht. Es gilt, die wenigen behandelbaren Primärtumoren zu erkennen (Brust, Keimzell, NHL). Empirische Behandlungsmethoden (Chemotherapie, Radiatio, Radikaloperationen) sind aufgrund des hohen Risikos im Vergleich zu mäßigem Erfolg nicht empfehlenswert. Für Arzt und Patient entsteht eine unbefriedigende Situation durch Minimieren der Diagnostik bei fehlenden Behandlungsmöglichkeiten.

Abstract

Cancer of unknown primary site (CUP) occurs in 0.4 % - 7 % of all tumors. Extensive and costly diagnostic protocolls only rarely lead to identification of the primary tumor and do not affect the mean actuarial survival. Merely palliative treatment is feasible for most patients. The few primary tumors that can be treated must be identified (breast, germinal cell, non-Hodgkin lymphoma). Empirical treatment methods (chemotherapy, radiation, radical operations) are inappropriate owing to the high risk in relation to poor success. An unsatisfactory situation ensues for both doctors and patients when diagnostics are minimized because treatment is unavailable.

Key words:

CUP - Retroperitoneal neoplasm - Unknown origin - Diagnostic techniques

Literatur

  • 1 Abbruzzese J L, Lenzi R, Raber M N, Pathak S, Frost P. The biology of unknown primary tumors.  Semin in Oncol. 1993;  20 Nr. 3 238-243
    PubMedGoogle Scholar
  • 2 Abbruzzese J L, Abbruzzese M C, Lenzi R, Hess K R, Raber M N. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.  J Clin Oncol. 1995;  13 Nr. 8 2094-2103
    PubMedGoogle Scholar
  • 3 Arnold A, Cossman J, Bakhshi A, Jaffe E S, Waldmann T A, Korsmeyer S J. Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms.  NEJM. 1983;  309 1593-1599
    PubMedGoogle Scholar
  • 4 Bosl G J, Dmitrovsky E, Reuter V, Samaniego F, Murty V VS, Chaganti R SK. A specific karyotypic abnormality in germ cell tumors.  Proc Am Soc Clin Oncol. 1989;  8 131 abstract
    PubMedGoogle Scholar
  • 5 Diggs C H. Cancer of unknown primary site.  Postgraduate Med. 1989;  86 Nr. 2 186-191
    PubMedGoogle Scholar
  • 6 Gatter K C, Alcock C, Heryet A, Mason D Y. Clinical importance of analysing malignant tumors of uncertain origin with immunohistochemical techniques.  Lancet. 1985;  1 1302-1305
    PubMedGoogle Scholar
  • 7 Gentile P S, Carloss H W, Huang T Y, Lam W K. Disseminated prostate carcinoma simulating primary lung cancer.  Cancer. 1988;  62 711-715
    PubMedGoogle Scholar
  • 8 Greco F A, Vaughn W K, Hainsworth J D. Advanced poorly differentiated carcinoma of unknown primary site: recognition of treatable Syndrome.  Ann Intern Med. 1986;  104 547-553
    PubMedGoogle Scholar
  • 9 Greco F A, Hainsworth J D. Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long term results with cisplatin-based chemotherapy.  Semin Oncol. 1994;  21 Suppl 12 77-82
    PubMedGoogle Scholar
  • 10 Greco F A, Hainsworth J D. The evolving role of paclitaxel for patients with carcinoma of unknown primary site.  Semin Oncol. 1999;  26 Suppl 2 129-133
    PubMedGoogle Scholar
  • 11 Grosbach A B. Carcinoma of unknown primary site.  Arch Intern Med. 1982;  142 357-359
    CrossrefPubMedGoogle Scholar
  • 12 Guarschi A, Keane T J, Elhakim T. Metastatic inguinal nodes from an unknown primary neoplasm: a review of 56 cases.  Cancer. 1987;  59 572-577
    PubMedGoogle Scholar
  • 13 Hainsworth J D, Johnson D H, Greco F A. Cisplatin-based chemotherapy in the treatment of poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.  J Clin Oncol. 1992;  10 912-922
    PubMedGoogle Scholar
  • 14 Hainsworth J D, Greco F A. Treatment of patients with cancer of unknown primary site.  NEJM. 1993;  329 Nr 4 257-263
    CrossrefPubMedGoogle Scholar
  • 15 Hainsworth J D, Greco F A. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site.  Semin Oncol. 1993;  20 Nr 3 279-286
    PubMedGoogle Scholar
  • 16 Jesse R H, Neff L E. Metastatic carcinoma in cervical nodes with an unknown primary site.  Am J Surg. 1996;  112 547-553
    PubMedGoogle Scholar
  • 17 Jordan III W E, Shildt R A. Adenocarcinoma of unknown primary site.  Cancer. 1985;  55 857-860
    PubMedGoogle Scholar
  • 18 Kafagiri H, Takahashi M, Inagaki J, Sugiura H, Ito S, Iwata H. Determining the site of the primary cancer in patients with skeletal metastasis of unknown origin.  Cancer. 1999;  86 Nr 3 533-537
    CrossrefPubMedGoogle Scholar
  • 19 Karsell P R, Sheedy II P F, O'Connell M J. Computed tomography in search of cancer of unknown origin.  JAMA. 1982;  248 Nr 3 340-343
    CrossrefPubMedGoogle Scholar
  • 20 König M, Shadouh S, Boeminghaus F. Das kleinzellige Harnblasenkarzinom.  Akt Urol. 1997;  27 422-425
    PubMedGoogle Scholar
  • 21 Kole A C, Nieweg O E, Pruim J, Hoekstra H J, Koops H S, Roodenburg J LN, Vaalburg W, Vermey W. Detection of unknown occult primary tumors using positron emission tomography.  Cancer. 1998;  82 Nr 6 1160-1166
    CrossrefPubMedGoogle Scholar
  • 22 Mackay B, Ordonez N G. The role of the pathologist in the evaluation of poorly differentiated tumors.  Semin in Oncol. 1982;  9 Nr 4 396-415
    PubMedGoogle Scholar
  • 23 Muir C. Cancer of unknown primary site.  Cancer. 1995;  suppl 75 Nr 1 353-356
    PubMedGoogle Scholar
  • 24 Nystrom J S, Weiner J M, Heffelfinger-Juttner J, Irwin L E, Bateman J RT, Wolf R M. Metastatic and histologic presentations in unknown primary cancer.  Semin in Oncol. 1977;  4 53-58
    PubMedGoogle Scholar
  • 25 Nystrom J S, Weiner J M, Wolf R M, Bateman J R, Viola M V. Identifying the primary site in metastatic cancer of unknown origin.  JAMA. 1979;  241 Nr 4 381-383
    CrossrefPubMedGoogle Scholar
  • 26 Ransom D T, Patel S R, Keeney G L, Malkasian G D, Edmonson J H. Papillary serous carcinoma in the peritoneum: a review of 33 cases treated with platin-based chemotherapy.  Cancer. 1990;  66 1091-1094
    PubMedGoogle Scholar
  • 27 Ringenberg S, Doll D C, Yarbo J W, Perry M C. Tumors of unknown origin in the bone.  Arch Intern Med. 1986;  146 2027-2028
    CrossrefPubMedGoogle Scholar
  • 28 Robert N J, Garnick M B, Frei III E. Cancers of unknown origin: Current approaches and future perspectives.  Semin in Oncol. 1982;  9 Nr 4 526-531
    PubMedGoogle Scholar
  • 29 Schapira D V, Jarrett A R. The need to consider survival, outcome and expense when evaluating and treating patients with unknown primary carcinoma.  Arch Inter Med. 1995;  155 2050-2054
    CrossrefPubMedGoogle Scholar
  • 30 Schlag P M, Hunerbein M. Cancer of unknown primary.  Ann Chir Gynaecol. 1994;  83 8-12
    PubMedGoogle Scholar
  • 31 Silverman C, Marks J E. Metastastic cancer of unknown origin: Epidermoid and undifferentiated carcinomas.  Semin in Oncol. 1982;  9 Nr 4 435-441
    PubMedGoogle Scholar
  • 32 Snyder R D, Mavligit G M, Valdivieso M. Adenocarcinoma of unknown primary site: A clinico-pathological study.  Med Pediatr Oncol. 1979;  6 289-294
    PubMedGoogle Scholar
  • 33 Solomon E, Borrow J, Goddard A D. Chromosome aberrations und cancer.  Science. 1991;  254 1153-1160
    PubMedGoogle Scholar
  • 34 Sporn J R, Greenberg B R. Empiric chemotherapy in patients with carcinoma of unknown primary site.  Am J Med. 1990;  88 49-55
    CrossrefPubMedGoogle Scholar
  • 35 Stewart J F, Tattersall M H, Woods R L. Unknown primary adenocarcinoma: Incidence of over investigation and natural history.  BMJ. 1979;  1 1530-1533
    PubMedGoogle Scholar
  • 36 Turc-Carel C, Philip I, Berger M P, Philip T, Lenoir G M. Chromosomal translocations in Ewing's sarcoma.  NEJM. 1983;  309 497-498
    PubMedGoogle Scholar
  • 37 van der Gaast A, Verweij J, Henzen-Logmans S C, Rodenberg C J, Stoter G. Carcinoma of unknown primary: Identification of a treatable subset.  Ann Oncol. 1990;  1 119-122
    PubMedGoogle Scholar
  • 38 Whang-Peng J, Triche T J, Knutsen T, Miser J, Douglass E C, Israel M A. Chromosome translocation in peripheral neuroepithelioma.  NEJM. 1984;  311 584-585
    PubMedGoogle Scholar
  • 39 Woods R L, Fox M B, Tattersall M HN, Levi J A, Brodie G N. Metastatic adenocarcinomas of unknown primary site.  NEJM. 1980;  303 Nr 2 87-89
    PubMedGoogle Scholar

Dr. Marc König

Urologische Klinik Städtische Kliniken Neuss

Preussenstr. 84

41464 Neuss

      >